Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). This study was pre-published online today in… Continue
Added by Peter Hofland, PhD on October 30, 2009 at 10:30pm —
In an effort to boost its image and further develop its R&D pipeline for new oncology products, Paris-based Sanofi-aventis signed a two-year service contract with Oncodesign Biotechnology.
Under the terms of the contract, Oncodesign Biotechnology, a specialist in the identification of novel cancer therapies which has developed an innovative preclinical… Continue
Added by Peter Hofland, PhD on October 28, 2009 at 8:00pm —
According to a report from the American Cancer Society, lung cancer, the world's most common cancer, will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.… Continue
Added by Peter Hofland, PhD on October 27, 2009 at 8:00pm —
The Side-Out Foundation, established in 2004 by a group of individuals drawn together by their love of volleyball and a passion to be a part of the war against breast cancer, and its Dig Pink® Volleyball Breast Cancer Awareness Campaign, will launch a first of its kind clinical trial this month to examine the effects of individualized treatment on patients with metastatic breast cancer. Individualized treatment, known as targeted therapy, provides doctors a better way to tailor cancer… Continue
Added by Peter Hofland, PhD on October 23, 2009 at 4:30pm —
As Americans mark this year the 25th anniversary of October as the National Breast Cancer Awareness Month, Secretary of Health and Human Services Kathleen Sebelius released a new report, Health Insurance Reform and Breast Cancer: Making the Health Care System Work for Women. The report details how health insurance reform will help women diagnosed with breast cancer.
Breast cancer patients face great uncertainty in the current health care system. Women diagnosed with… Continue
Added by Peter Hofland, PhD on October 23, 2009 at 2:13pm —
Earlier this month recruitment has begun to enroll patients in an international Phase III trial to evaluate sorafenib (Nexavar®) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular and Hurthle cell). The study is scheduled to start later this month at sites in the United States, Europe, Asia, and Japan. The study is schedules to complete in November 2011.
Added by Peter Hofland, PhD on October 23, 2009 at 2:08pm —
Scientists at GE Global Research
, onf of the world's most diversified industrial research labs, and researchers at Eli Lilly & Company
, a leading innovation-driven pharmaceutical products company, have developed tissue-based biomarker technology that for the first time can simultaneously map more than 25 proteins in tumors at the sub-cellular level, an important step in the… Continue
Added by Peter Hofland, PhD on October 21, 2009 at 8:00pm —
The U.S. Food and Drug Administration today approved pazopanib (Votrient®, GW786034; GlaxoSmithKline), the sixth drug to be approved for kidney cancer since 2005.
Pazopanib, is an oral medication that selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis, or growth of new blood vessels, in tumors in which these receptors are… Continue
Added by Peter Hofland, PhD on October 19, 2009 at 7:30am —
There is concern that mastectomy is over-utilized in the United States, which raises questions about the role of surgeons and patient preference in treatment selection for breast cancer. New data from an observational study found that breast-conserving surgery was presented and provided in the majority of patients evaluated. Surgeon recommendations, patient decisions, and failure of breast-conserving surgery were all found to be contributing factors to the mastectomy… Continue
Added by Peter Hofland, PhD on October 13, 2009 at 3:30pm —
Researchers have validated a new method of tissue analysis, called tissue microarrays, to determine the 'intrinsic subtype' of a breast tumor and to predict whether a patient with breast cancer that has spread to the lymph nodes will benefit from adjuvant paclitaxel (Taxol) chemotherapy.
Use of breast cancer subtyping to predict response to a specific anticancer drug will improve physicians’ ability to personalize treatment to maximize benefits and spare patients from… Continue
Added by Peter Hofland, PhD on October 8, 2009 at 2:30pm —
Researchers in the United Kingdom have shown that the addition of axillary ultrasound prior to initial breast-conserving surgery spared nearly one-third of women with early-stage breast cancer who had underarm (axillary) lymph node metastases from a second breast cancer surgery to remove additional axillary nodes.
The study found that axillary ultrasound (AUS) can be useful for detecting large deposits of cancer cells, called macrometastases, in axillary lymph nodes,… Continue
Added by Peter Hofland, PhD on October 6, 2009 at 6:00pm —
Women under age 44 with DCIS have a higher risk of recurrence. A large population-based study by of younger women with ductal carcinoma in situ (DCIS), a pre-invasive form of early-stage breast cancer, has found that women age 44 and younger have almost double the risk of recurrence following breast conservation surgery and radiation therapy than women age 45 to 50, whose rates were similar to known rates of women over 50.
“We don’t yet know why younger women with DCIS… Continue
Added by Peter Hofland, PhD on October 6, 2009 at 5:30pm —
Results from new studies on the early detection, evaluation and treatment of breast cancer released during the 2009 (third) Breast Cancer Symposium, held at the San Francisco Marriott from October 8-10, 2009, highlighted that the majority of breast cancer deaths occur among women who don’t receive regular mammography.
A large, retrospective population-based study has found that nearly three-quarters of breast cancer deaths occur among the minority of women who do not… Continue
Added by Peter Hofland, PhD on October 6, 2009 at 5:00pm —
The National Breast Cancer Coalition (NBCC) has launched the 31 Myths & Truths in 31 Days campaign to challenge women and men to get educated, speak up and to take action to cure breast cancer. The new campaign is designed to dispels commonly believed myths and reveals relatively unknown truths about breast cancer.
The National Breast Cancer Coalition has a long history of challenging the status quo in the science and public policy of breast cancer. Throughout… Continue
Added by Peter Hofland, PhD on October 2, 2009 at 10:00pm —
Cancer is a major cause of ill health within the EU, yet co-ordinated attempts to tackle it have been thin on the ground until now. At a dinner workshop at the European Health Forum Gastein (Dinner Workshop 1: “The unified approach: meeting the cancer challenges in the next decade”, European Health Forum Gastein, Thursday 1st October, 2009 – Congress Centre, Room 2 – 18.00-20.30), speakers from the European CanCer Organisation (ECCO), set out their plans to tackle this cancer and to… Continue
Added by Peter Hofland, PhD on October 2, 2009 at 6:30pm —
French pharmaceutical company Sanofi-aventis (Paris, France) and Merrimack Pharmaceuticals Inc., a privately-held biotechnology company based in Cambridge, Massachusetts focusing on the discovery and development of novel treatments for cancer and autoimmune diseases, have entered in an exclusive global collaboration and licensing agreement on MM-121, a first-in-class,… Continue
Added by Peter Hofland, PhD on October 1, 2009 at 8:00pm —